Developer docs
API playgroundTry for free, no card

Search company profiles

Nospharma

Full company profile

uuid000f4dl

Namestring
Nospharma
Legal namestring
Nospharma
Websiteurl
nospharma.ca
Company typeenum
Private
Founded yearint
2021
Descriptiontext

Nospharma is a preclinical-stage biopharmaceutical company developing novel small-molecule and peptide therapeutics for rare genetic neurological disorders. The company's lead asset, NOS-01, is a small-molecule therapeutic that works by restoring downstream signaling of glutamatergic synapses and is being evaluated across multiple genetically defined indications including Fragile X Syndrome, SYNGAP1-Related Disorder, GRIN Disorder, and Phelan-McDermid Syndrome. Nospharma employs a multi-therapeutic approach — combining multiple small-molecules and peptides that each target a distinct biological underpinning of a given disorder — alongside therapeutic repurposing to compress clinical development timelines and costs. Clinical endpoints are being informed by patient input, and the company targets conditions with no approved drug treatments today.

Founded in 2021 in Montréal, Canada by neuroscientist-entrepreneur Anmol Nagpal (CEO) and Dr. Derek Bowie, Canada Research Chair in Receptor Pharmacology and Professor of Pharmacology and Therapeutics at McGill University, Nospharma operates as a spin-off of the Bowie Lab at McGill. The company's R&D is closely integrated with McGill's neuroscience innovation infrastructure (NeuroSphere, Healthy Brains Healthy Lives), and it has secured grant funding and research partnerships from rare-disease patient advocacy foundations including Overcome SYNGAP1, SynGAP Research Fund, Wandoan Campdraft for a Cure, cureGRIN Foundation, and FRAXA Research Foundation. It also participates in the District 3 Innovation Launch & Grow accelerator and is supported by the Quebec innovation network.

Nospharma is pre-revenue with no commercial products, no disclosed pricing, and no commercial distribution. Funding to date consists exclusively of non-dilutive grants from patient foundations (cumulative ~$175K disclosed). The go-to-market model for the pipeline is co-development and licensing to established biopharma partners rather than independent commercialization. Headcount is 1–10 employees, with executive leadership comprising Nagpal, Bowie, and Head of Corporate Development David Baker (formerly VP/Global GM Vyvanse and CEO at Shire, Alcobra, and Vallon Pharmaceuticals), plus IP, regulatory, and communications advisors.

Short descriptiontext

Nospharma is a preclinical-stage biopharmaceutical company in Montréal developing novel small-molecule and peptide therapeutics, led by asset NOS-01, for rare genetic neurological disorders including Fragile X Syndrome, SYNGAP1, GRIN Disorder, and Phelan-McDermid Syndrome.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersMontreal, Canada
HQ citystring
Montreal
HQ countrystring
Canada
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
rare neurological therapeutics, small molecule drug discovery, peptide therapeutic development, preclinical biotechnology, genetic disorder treatment
Industry2 codes
PRIMARYHLAIACAC
Neurology & CNS Specialty Pharmaceuticals
SECONDARYHLAIAIAA
Genetic & Genomic Rare Disease Therapeutics
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Services-Health Services8000
Product category
Rare Disease Therapeutics
Social media profiles1 record
Marketing channels2 records

Each record includes

Title, Type, Stage, Description, Source

Cost components4 values
Personnel, Technology or R&D, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Nospharma is a preclinical-stage therapeutics company developing novel small-molecule and peptide therapeutics for rare genetic neurological disorders including Fragile X Syndrome, SYNGAP1-Related Disorder, GRIN Disorder, and Phelan-McDermid Syndrome. The lead asset NOS-01 is a small-molecule therapeutic designed to restore downstream signaling of glutamatergic synapses, and the company applies a multi-therapeutic approach combining multiple compounds to target distinct biological underpinnings of each disorder.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Nospharma is a preclinical stage therapeutics company developing innovative treatments for rare genetic neurological disorders. The company's product portfolio centers on NOS-01, its lead small-molecule therapeutic asset, along with a pipeline of novel small-molecule and peptide therapeutics. The company employs a multi-therapeutic approach, targeting multiple biological mechanisms within each disorder to enhance treatment effectiveness. NOS-01 is being developed for Fragile X Syndrome, SYNGAP1-related disorders, and GRIN disorders, representing genetically defined markets with major unmet medical needs.

Product and service2 records
1NOS-01
CategoryRare Disease Therapeutics
Description

NOS-01 is Nospharma's lead small-molecule therapeutic asset in preclinical development for the treatment of rare genetic neurological disorders including Fragile X Syndrome, SYNGAP1-Related Disorder, and GRIN Disorder. It works by restoring downstream signaling of glutamatergic synapses in the brain and is being validated in mouse and cellular models through partnerships with FRAXA Research Foundation, cureGRIN Foundation, and SynGAP Research Fund-affiliated organizations.

2Multi-therapeutic pipeline of novel small-molecule and peptide therapeutics
CategoryRare Disease Therapeutics
Description

Broader pipeline of novel small-molecule and peptide therapeutics targeting rare genetic neurological disorders (Fragile X Syndrome, SYNGAP1-Related Disorder, GRIN Disorder, and Phelan-McDermid Syndrome) using a multi-therapeutic approach in which multiple compounds each target a unique biological underpinning of a given disorder to create medicines with enhanced effectiveness.

Partnership8 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-02-04
Description

Strategic collaboration to conduct pre-clinical testing of NOS-01, Nospharma's lead asset, in Fragile X Syndrome mouse models. The partnership utilizes FRAXA's standardized preclinical testing platform to validate NOS-01's efficacy and accelerate development toward clinical trials.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-03-01
Description

$25k partnership to test NOS-01 as a potential treatment for GRIN disorders in preclinical animal and cell models. The collaboration aims to advance medical research for rare neurological conditions and deliver new therapies to patients with GRIN disorders. Work led by CSO Dr. Derek Bowie.

3District 3 Innovation
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2022-10-20
Description

Competitively selected to join District 3 Innovation Launch & Grow program with 2 years of individualized support, workshops, VC and angel investor access, and subject-matter expert guidance. CEO Anmol Nagpal awarded a Fellowship to work with D3 team supporting life-science startups.

nospharma.ca
4Overcome SYNGAP1, Wandoan Campdraft for a Cure, SynGAP Research Fund Australia, SynGAP Research Fund
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-07-27
Description

Joint $150,000 grant awarded to the McGill University lab of CSO Dr. Derek Bowie for preclinical studies to validate NOS-01 therapeutic potential to treat SYNGAP1-related disorders by restoring downstream signalling of glutamatergic synapses in SynGAP1 mouse and cellular models.

nospharma.ca
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Deep partnership with McGill University's Bowie Lab led by CSO Dr. Derek Bowie, who is Professor of Pharmacology and Therapeutics at McGill and Co-Director of the Cell Information Systems. Research focuses on ion channel biology and neurophysiology for rare neurological disorders.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

McGill's neuroscience-focused innovation hub supporting biotech spin-off companies including Nospharma.

7Healthy Brains, Healthy Lives (HBHL)
Strategic tierMinorTypeStrategic or Co-development Partner
Description

McGill University initiative supporting neuroscience research and innovation ecosystem.

nospharma.ca
8Mouvement des accélérateurs d'innovation du Québec
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Quebec innovation accelerator network supporting biotech startups in the province.

nospharma.ca
Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Anavex is a clinical-stage biopharma developing small-molecule therapeutics for rare neurological and neurodegenerative diseases including Rett syndrome, Fragile X-associated disorders, and Parkinson's disease dementia. Highly comparable to Nospharma in target indication space, small-molecule modality, and rare CNS focus.

TypeDirect peer
Description

Zynerba developed Zygel, a transdermal CBD therapy specifically for Fragile X Syndrome and 22q11.2 deletion syndrome. Direct indication overlap with Nospharma's NOS-01 lead program in Fragile X and adjacent rare neurodevelopmental disorders.

TypeDirect peer
Description

Healx is an AI-driven drug discovery company focused exclusively on rare diseases, with active programs including Fragile X Syndrome using a combination-and-repurposing approach similar to Nospharma's methodology. Direct strategic and methodological peer.

TypeDirect peer
Description

Marinus developed ZTALMY (ganaxolone) for CDKL5 deficiency disorder, a rare genetic epilepsy, and is exploring adjacent rare pediatric neurodevelopmental epilepsies. Comparable in targeting rare genetically-defined CNS disorders with no prior approved therapies.

TypeBroad incumbent
Description

Praxis is a clinical-stage CNS biotech leveraging genetics and translational science to develop precision therapies across epilepsies and rare neurodevelopmental disorders. Comparable therapeutic area, but operates at broader scale with multiple clinical-stage assets.

TypeBroad incumbent
Description

BioMarin is an established global rare-disease biopharma with active CNS programs and historical leadership in orphan drug commercialization. Comparable in rare-disease go-to-market expertise, though substantially larger and broader in portfolio than Nospharma.

TypeBroad incumbent
Description

Ultragenyx is a commercial-stage rare-disease biotech with multiple approved therapies and CNS/neuromuscular rare-disease pipeline. Comparable in rare-disease commercialization strategy, but with broader therapeutic footprint and clinical-stage assets.

TypeEmerging player
Description

Voyager is a clinical-stage gene therapy company focused on CNS disorders including Huntington's disease and Alzheimer's. Comparable CNS rare-disease focus but uses gene-therapy modality, complementing Nospharma's small-molecule approach.

TypeBroad incumbent
Description

Ionis is a leader in antisense oligonucleotide (ASO) therapeutics, with approved and clinical-stage CNS programs including for rare neurological genetic disorders. Comparable in rare CNS genetics-based drug development, but uses ASO modality versus Nospharma's small-molecule/peptides.

TypeEmerging player
Description

Neumora is a clinical-stage precision neurology company developing brain-targeted therapeutics for neuropsychiatric and rare CNS disorders. Operates in adjacent neuroscience precision-medicine space with broader CNS pipeline targeting.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Nospharma

Rare Disease Therapeuticsnospharma.ca

Nospharma is a preclinical-stage biopharmaceutical company in Montréal developing novel small-molecule and peptide therapeutics, led by asset NOS-01, for rare genetic neurological disorders including Fragile X Syndrome, SYNGAP1, GRIN Disorder, and Phelan-McDermid Syndrome.

What Nospharma does

Nospharma is a preclinical-stage biopharmaceutical company developing novel small-molecule and peptide therapeutics for rare genetic neurological disorders. The company's lead asset, NOS-01, is a small-molecule therapeutic that works by restoring downstream signaling of glutamatergic synapses and is being evaluated across multiple genetically defined indications including Fragile X Syndrome, SYNGAP1-Related Disorder, GRIN Disorder, and Phelan-McDermid Syndrome. Nospharma employs a multi-therapeutic approach — combining multiple small-molecules and peptides that each target a distinct biological underpinning of a given disorder — alongside therapeutic repurposing to compress clinical development timelines and costs. Clinical endpoints are being informed by patient input, and the company targets conditions with no approved drug treatments today.

Founded in 2021 in Montréal, Canada by neuroscientist-entrepreneur Anmol Nagpal (CEO) and Dr. Derek Bowie, Canada Research Chair in Receptor Pharmacology and Professor of Pharmacology and Therapeutics at McGill University, Nospharma operates as a spin-off of the Bowie Lab at McGill. The company's R&D is closely integrated with McGill's neuroscience innovation infrastructure (NeuroSphere, Healthy Brains Healthy Lives), and it has secured grant funding and research partnerships from rare-disease patient advocacy foundations including Overcome SYNGAP1, SynGAP Research Fund, Wandoan Campdraft for a Cure, cureGRIN Foundation, and FRAXA Research Foundation. It also participates in the District 3 Innovation Launch & Grow accelerator and is supported by the Quebec innovation network.

Nospharma is pre-revenue with no commercial products, no disclosed pricing, and no commercial distribution. Funding to date consists exclusively of non-dilutive grants from patient foundations (cumulative ~$175K disclosed). The go-to-market model for the pipeline is co-development and licensing to established biopharma partners rather than independent commercialization. Headcount is 1–10 employees, with executive leadership comprising Nagpal, Bowie, and Head of Corporate Development David Baker (formerly VP/Global GM Vyvanse and CEO at Shire, Alcobra, and Vallon Pharmaceuticals), plus IP, regulatory, and communications advisors.

Nospharma firmographics

Firmographics
Name
Nospharma
Legal name
Nospharma
Website
https://nospharma.ca
Company type
Private
Founded year
2021
Operating status
Operating
Headcount range
1–10 employees
Short description
Nospharma is a preclinical-stage biopharmaceutical company in Montréal developing novel small-molecule and peptide therapeutics, led by asset NOS-01, for rare genetic neurological disorders including Fragile X Syndrome, SYNGAP1, GRIN Disorder, and Phelan-McDermid Syndrome.
Ownership category
akta.pro rank

Nospharma industry classification

Industry
Product category
Rare Disease Therapeutics
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Services-Health Services (8000)
akta.pro industry
PRIMARYHLAIACAC
Neurology & CNS Specialty Pharmaceuticals
SECONDARYHLAIAIAA
Genetic & Genomic Rare Disease Therapeutics
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals

Keywords

  • Rare neurological therapeutics
  • Small molecule drug discovery
  • Peptide therapeutic development
  • Preclinical biotechnology
  • Genetic disorder treatment

Where Nospharma is headquartered

Location

Headquarters

HQ city
Montreal
HQ country
Canada
HQ region
North America

Markets served

Nospharma business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales

Marketing channels2 records

Nospharma product offering

Product offering

Core offering

Nospharma is a preclinical-stage therapeutics company developing novel small-molecule and peptide therapeutics for rare genetic neurological disorders including Fragile X Syndrome, SYNGAP1-Related Disorder, GRIN Disorder, and Phelan-McDermid Syndrome. The lead asset NOS-01 is a small-molecule therapeutic designed to restore downstream signaling of glutamatergic synapses, and the company applies a multi-therapeutic approach combining multiple compounds to target distinct biological underpinnings of each disorder.

Product overview

Nospharma is a preclinical stage therapeutics company developing innovative treatments for rare genetic neurological disorders. The company's product portfolio centers on NOS-01, its lead small-molecule therapeutic asset, along with a pipeline of novel small-molecule and peptide therapeutics. The company employs a multi-therapeutic approach, targeting multiple biological mechanisms within each disorder to enhance treatment effectiveness. NOS-01 is being developed for Fragile X Syndrome, SYNGAP1-related disorders, and GRIN disorders, representing genetically defined markets with major unmet medical needs.

Differentiator

Problem solved

Functional benefit

Products and services

  • NOS-01 NOS-01 is Nospharma's lead small-molecule therapeutic asset in preclinical development for the treatment of rare genetic neurological disorders including Fragile X Syndrome, SYNGAP1-Related Disorder, and GRIN Disorder. It works by restoring downstream signaling of glutamatergic synapses in the brain and is being validated in mouse and cellular models through partnerships with FRAXA Research Foundation, cureGRIN Foundation, and SynGAP Research Fund-affiliated organizations.
  • Multi-therapeutic pipeline of novel small-molecule and peptide therapeutics Broader pipeline of novel small-molecule and peptide therapeutics targeting rare genetic neurological disorders (Fragile X Syndrome, SYNGAP1-Related Disorder, GRIN Disorder, and Phelan-McDermid Syndrome) using a multi-therapeutic approach in which multiple compounds each target a unique biological underpinning of a given disorder to create medicines with enhanced effectiveness.

Companies that use Nospharma

Customer profile

Segments1 record

Ideal customer profiles2 records

Nospharma technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

Nospharma partnerships and signals

Strategic signal

Partnerships

Eight partnerships are on record, tiered core and minor.

  • FRAXA Research FoundationcoreStrategic or Co-development Partner · 4 February 2026Strategic collaboration to conduct pre-clinical testing of NOS-01, Nospharma's lead asset, in Fragile X Syndrome mouse models. The partnership utilizes FRAXA's standardized preclinical testing platform to validate NOS-01's efficacy and accelerate development toward clinical trials.
  • cureGRIN FoundationcoreStrategic or Co-development Partner · 1 March 2024$25k partnership to test NOS-01 as a potential treatment for GRIN disorders in preclinical animal and cell models. The collaboration aims to advance medical research for rare neurological conditions and deliver new therapies to patients with GRIN disorders. Work led by CSO Dr. Derek Bowie.
  • District 3 InnovationminorStrategic or Co-development Partner · 20 October 2022Competitively selected to join District 3 Innovation Launch & Grow program with 2 years of individualized support, workshops, VC and angel investor access, and subject-matter expert guidance. CEO Anmol Nagpal awarded a Fellowship to work with D3 team supporting life-science startups.
  • Overcome SYNGAP1, Wandoan Campdraft for a Cure, SynGAP Research Fund Australia, SynGAP Research FundcoreStrategic or Co-development Partner · 27 July 2022Joint $150,000 grant awarded to the McGill University lab of CSO Dr. Derek Bowie for preclinical studies to validate NOS-01 therapeutic potential to treat SYNGAP1-related disorders by restoring downstream signalling of glutamatergic synapses in SynGAP1 mouse and cellular models.
  • McGill University (Bowie Lab)coreStrategic or Co-development PartnerDeep partnership with McGill University's Bowie Lab led by CSO Dr. Derek Bowie, who is Professor of Pharmacology and Therapeutics at McGill and Co-Director of the Cell Information Systems. Research focuses on ion channel biology and neurophysiology for rare neurological disorders.
  • NeuroSphere McGillminorStrategic or Co-development PartnerMcGill's neuroscience-focused innovation hub supporting biotech spin-off companies including Nospharma.
  • Healthy Brains, Healthy Lives (HBHL)minorStrategic or Co-development PartnerMcGill University initiative supporting neuroscience research and innovation ecosystem.
  • Mouvement des accélérateurs d'innovation du QuébecminorStrategic or Co-development PartnerQuebec innovation accelerator network supporting biotech startups in the province.

Recent moves5 records

Expansion highlights4 records

Nospharma competitors and assessment

Company assessment

Direct peers

  • Anavex Life Sciences: Anavex is a clinical-stage biopharma developing small-molecule therapeutics for rare neurological and neurodegenerative diseases including Rett syndrome, Fragile X-associated disorders, and Parkinson's disease dementia. Highly comparable to Nospharma in target indication space, small-molecule modality, and rare CNS focus.
  • Zynerba Pharmaceuticals: Zynerba developed Zygel, a transdermal CBD therapy specifically for Fragile X Syndrome and 22q11.2 deletion syndrome. Direct indication overlap with Nospharma's NOS-01 lead program in Fragile X and adjacent rare neurodevelopmental disorders.
  • Healx: Healx is an AI-driven drug discovery company focused exclusively on rare diseases, with active programs including Fragile X Syndrome using a combination-and-repurposing approach similar to Nospharma's methodology. Direct strategic and methodological peer.
  • Marinus Pharmaceuticals: Marinus developed ZTALMY (ganaxolone) for CDKL5 deficiency disorder, a rare genetic epilepsy, and is exploring adjacent rare pediatric neurodevelopmental epilepsies. Comparable in targeting rare genetically-defined CNS disorders with no prior approved therapies.

Broad incumbents

  • Praxis Precision Medicines: Praxis is a clinical-stage CNS biotech leveraging genetics and translational science to develop precision therapies across epilepsies and rare neurodevelopmental disorders. Comparable therapeutic area, but operates at broader scale with multiple clinical-stage assets.
  • BioMarin Pharmaceutical: BioMarin is an established global rare-disease biopharma with active CNS programs and historical leadership in orphan drug commercialization. Comparable in rare-disease go-to-market expertise, though substantially larger and broader in portfolio than Nospharma.
  • Ultragenyx Pharmaceutical: Ultragenyx is a commercial-stage rare-disease biotech with multiple approved therapies and CNS/neuromuscular rare-disease pipeline. Comparable in rare-disease commercialization strategy, but with broader therapeutic footprint and clinical-stage assets.
  • Ionis Pharmaceuticals: Ionis is a leader in antisense oligonucleotide (ASO) therapeutics, with approved and clinical-stage CNS programs including for rare neurological genetic disorders. Comparable in rare CNS genetics-based drug development, but uses ASO modality versus Nospharma's small-molecule/peptides.

Emerging players

  • Voyager Therapeutics: Voyager is a clinical-stage gene therapy company focused on CNS disorders including Huntington's disease and Alzheimer's. Comparable CNS rare-disease focus but uses gene-therapy modality, complementing Nospharma's small-molecule approach.
  • Neumora Therapeutics: Neumora is a clinical-stage precision neurology company developing brain-targeted therapeutics for neuropsychiatric and rare CNS disorders. Operates in adjacent neuroscience precision-medicine space with broader CNS pipeline targeting.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

Nospharma social profiles

Digital presence

Nospharma financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Nospharma leadership team

Management profile

Number of profiles

Profiles3 records

Nospharma funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Nospharma M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Nospharma

What does Nospharma do?

Nospharma is a preclinical-stage therapeutics company developing novel small-molecule and peptide therapeutics for rare genetic neurological disorders including Fragile X Syndrome, SYNGAP1-Related Disorder, GRIN Disorder, and Phelan-McDermid Syndrome. The lead asset NOS-01 is a small-molecule therapeutic designed to restore downstream signaling of glutamatergic synapses, and the company applies a multi-therapeutic approach combining multiple compounds to target distinct biological underpinnings of each disorder.

Is Nospharma a public or private company?

Nospharma is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Nospharma founded?

Nospharma was founded in 2021. It employs 1 to 10 people.

Where is Nospharma based?

Nospharma is headquartered in Montreal, Canada, in the North America region.

Who are Nospharma's main competitors?

Direct peers on record are Anavex Life Sciences, Zynerba Pharmaceuticals, Healx and Marinus Pharmaceuticals. Broad incumbents are Praxis Precision Medicines, BioMarin Pharmaceutical, Ultragenyx Pharmaceutical and Ionis Pharmaceuticals. Emerging players are Voyager Therapeutics and Neumora Therapeutics.

Does Nospharma have an API?

No public API is recorded for Nospharma.

What industry is Nospharma in?

Nospharma's product category is Rare Disease Therapeutics. Its primary akta.pro industry code is HLAIACAC, Neurology & CNS Specialty Pharmaceuticals, with a secondary code of HLAIAIAA, Genetic & Genomic Rare Disease Therapeutics. Its NAICS code is 541714 and its SIC code is 8000.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals